INmune Bio Inc (INMB) USD0.001
INmune Bio, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. The Company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. The Company’s product platforms utilize a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.